Literature DB >> 32484892

Improving translational research in sex-specific effects of comorbidities and risk factors in ischaemic heart disease and cardioprotection: position paper and recommendations of the ESC Working Group on Cellular Biology of the Heart.

Cinzia Perrino1, Péter Ferdinandy2,3, Hans E Bøtker4, Bianca J J M Brundel5, Peter Collins6,7, Sean M Davidson8, Hester M den Ruijter9, Felix B Engel10, Eva Gerdts11, Henrique Girao12,13, Mariann Gyöngyösi14, Derek J Hausenloy15,16,17,18,19, Sandrine Lecour20, Rosalinda Madonna21,22, Michael Marber23, Elizabeth Murphy24, Maurizio Pesce25, Vera Regitz-Zagrosek26,27, Joost P G Sluijter28,29, Sabine Steffens30, Can Gollmann-Tepeköylü31, Linda W Van Laake32, Sophie Van Linthout33,34,35, Rainer Schulz36, Kirsti Ytrehus37.   

Abstract

Ischaemic heart disease (IHD) is a complex disorder and a leading cause of death and morbidity in both men and women. Sex, however, affects several aspects of IHD, including pathophysiology, incidence, clinical presentation, diagnosis as well as treatment and outcome. Several diseases or risk factors frequently associated with IHD can modify cellular signalling cascades, thus affecting ischaemia/reperfusion injury as well as responses to cardioprotective interventions. Importantly, the prevalence and impact of risk factors and several comorbidities differ between males and females, and their effects on IHD development and prognosis might differ according to sex. The cellular and molecular mechanisms underlying these differences are still poorly understood, and their identification might have important translational implications in the prediction or prevention of risk of IHD in men and women. Despite this, most experimental studies on IHD are still undertaken in animal models in the absence of risk factors and comorbidities, and assessment of potential sex-specific differences are largely missing. This ESC WG Position Paper will discuss: (i) the importance of sex as a biological variable in cardiovascular research, (ii) major biological mechanisms underlying sex-related differences relevant to IHD risk factors and comorbidities, (iii) prospects and pitfalls of preclinical models to investigate these associations, and finally (iv) will provide recommendations to guide future research. Although gender differences also affect IHD risk in the clinical setting, they will not be discussed in detail here. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardioprotection  Sex differences  Ischaemic heart disease  Ischaemia and reperfusion  Translational research  Comorbidities

Mesh:

Year:  2021        PMID: 32484892      PMCID: PMC7820844          DOI: 10.1093/cvr/cvaa155

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  334 in total

1.  Non-nuclear estrogen receptor alpha activation in endothelium reduces cardiac ischemia-reperfusion injury in mice.

Authors:  Sara Menazza; Junhui Sun; Swathi Appachi; Ken L Chambliss; Sung Hoon Kim; Angel Aponte; Sohaib Khan; John A Katzenellenbogen; Benita S Katzenellenbogen; Philip W Shaul; Elizabeth Murphy
Journal:  J Mol Cell Cardiol       Date:  2017-04-27       Impact factor: 5.000

2.  Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females.

Authors:  Claudia J Lagranha; Anne Deschamps; Angel Aponte; Charles Steenbergen; Elizabeth Murphy
Journal:  Circ Res       Date:  2010-04-22       Impact factor: 17.367

3.  Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome.

Authors:  Andromachi Vryonidou; Athanasios Papatheodorou; Anna Tavridou; Thomais Terzi; Vasiliki Loi; Ioannis-Anastasios Vatalas; Nikolaos Batakis; Constantinos Phenekos; Amalia Dionyssiou-Asteriou
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

4.  Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study.

Authors:  M Aboud; A Elgalib; L Pomeroy; G Panayiotakopoulos; E Skopelitis; R Kulasegaram; C Dimian; F C Lampe; A Duncan; A S Wierzbicki; B S Peters
Journal:  Int J Clin Pract       Date:  2010-08       Impact factor: 2.503

5.  Preconditioning protects the heart in a prolonged uremic condition.

Authors:  Gabriella F Kocsis; Márta Sárközy; Péter Bencsik; Márton Pipicz; Zoltán V Varga; János Pálóczi; Csaba Csonka; Péter Ferdinandy; Tamás Csont
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-09-14       Impact factor: 4.733

6.  Thyroid hormone improves postischaemic recovery of function while limiting apoptosis: a new therapeutic approach to support hemodynamics in the setting of ischaemia-reperfusion?

Authors:  Constantinos Pantos; Iordanis Mourouzis; Theodosios Saranteas; Guillaume Clavé; Heidi Ligeret; Pauline Noack-Fraissignes; Pierre-Yves Renard; Marc Massonneau; Philipos Perimenis; Danai Spanou; Georgia Kostopanagiotou; Dennis V Cokkinos
Journal:  Basic Res Cardiol       Date:  2008-12-20       Impact factor: 17.165

7.  Landscape of X chromosome inactivation across human tissues.

Authors:  Taru Tukiainen; Alexandra-Chloé Villani; Angela Yen; Manuel A Rivas; Jamie L Marshall; Rahul Satija; Matt Aguirre; Laura Gauthier; Mark Fleharty; Andrew Kirby; Beryl B Cummings; Stephane E Castel; Konrad J Karczewski; François Aguet; Andrea Byrnes; Tuuli Lappalainen; Aviv Regev; Kristin G Ardlie; Nir Hacohen; Daniel G MacArthur
Journal:  Nature       Date:  2017-10-11       Impact factor: 49.962

Review 8.  Cardiovascular disease in autoimmune rheumatic diseases.

Authors:  Ivana Hollan; Pier Luigi Meroni; Joseph M Ahearn; J W Cohen Tervaert; Sam Curran; Carl S Goodyear; Knut A Hestad; Bashar Kahaleh; Marcello Riggio; Kelly Shields; Mary C Wasko
Journal:  Autoimmun Rev       Date:  2013-03-27       Impact factor: 9.754

9.  Aromatase inhibition attenuates desflurane-induced preconditioning against acute myocardial infarction in male mouse heart in vivo.

Authors:  Virginija Jazbutyte; Jan Stumpner; Andreas Redel; Johan M Lorenzen; Norbert Roewer; Thomas Thum; Franz Kehl
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

Review 10.  Type 1 diabetes and cardiovascular disease.

Authors:  Oliver Schnell; Francesco Cappuccio; Stefano Genovese; Eberhard Standl; Paul Valensi; Antonio Ceriello
Journal:  Cardiovasc Diabetol       Date:  2013-10-28       Impact factor: 9.951

View more
  18 in total

1.  Risk factors, co-morbidities, and co-medications in cardioprotection: Importance for translation.

Authors:  Rainer Schulz; Ioanna Andreadou; Derek J Hausenloy; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2020-12       Impact factor: 8.739

Review 2.  Illuminating the Mechanisms Underlying Sex Differences in Cardiovascular Disease.

Authors:  Karen Reue; Carrie B Wiese
Journal:  Circ Res       Date:  2022-06-09       Impact factor: 23.213

3.  Testosterone-to-estradiol ratio and platelet thromboxane release in ischemic heart disease: the EVA project.

Authors:  V Raparelli; C Nocella; M Proietti; G F Romiti; B Corica; S Bartimoccia; L Stefanini; A Lenzi; N Viceconte; G Tanzilli; V Cammisotto; L Pilote; R Cangemi; S Basili; R Carnevale
Journal:  J Endocrinol Invest       Date:  2022-03-09       Impact factor: 5.467

Review 4.  Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities.

Authors:  Laura A Bienvenu; Jonathan Noonan; Xiaowei Wang; Karlheinz Peter
Journal:  Cardiovasc Res       Date:  2020-12-01       Impact factor: 10.787

Review 5.  Mouse models of atherosclerosis and their suitability for the study of myocardial infarction.

Authors:  Pelin Golforoush; Derek M Yellon; Sean M Davidson
Journal:  Basic Res Cardiol       Date:  2020-11-30       Impact factor: 17.165

Review 6.  Targeting the Endothelium to Achieve Cardioprotection.

Authors:  Nicolas Herrera-Zelada; Ursula Zuñiga-Cuevas; Andres Ramirez-Reyes; Sergio Lavandero; Jaime A Riquelme
Journal:  Front Pharmacol       Date:  2021-02-02       Impact factor: 5.810

Review 7.  Extracellular Vesicles in Comorbidities Associated with Ischaemic Heart Disease: Focus on Sex, an Overlooked Factor.

Authors:  Claudia Penna; Saveria Femminò; Giuseppe Alloatti; Maria F Brizzi; Tommaso Angelone; Pasquale Pagliaro
Journal:  J Clin Med       Date:  2021-01-17       Impact factor: 4.241

8.  Sex-Specific Alterations in Cardiac DNA Methylation in Adult Mice by Perinatal Lead Exposure.

Authors:  Laurie K Svoboda; Kai Wang; Tamara R Jones; Justin A Colacino; Maureen A Sartor; Dana C Dolinoy
Journal:  Int J Environ Res Public Health       Date:  2021-01-12       Impact factor: 4.614

9.  Evaluating the effects of carbon monoxide releasing molecule-2 against myocardial ischemia-reperfusion injury in ovariectomized female rats.

Authors:  Arthi Kumar; Sri Rahavi Boovarahan; Priyanka N Prem; Meenakshi Ramanathan; David Raj Chellappan; Gino A Kurian
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-08-02       Impact factor: 3.000

Review 10.  Testosterone, cardiomyopathies, and heart failure: a narrative review.

Authors:  Rodica Diaconu; Ionuţ Donoiu; Oana Mirea; Tudor Adrian Bălşeanu
Journal:  Asian J Androl       Date:  2021 Jul-Aug       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.